MindMed Announces New Employee Inducement Grants
MNMD(NASDAQ:MNMD) NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 78,750 common shares of the Company (the "Options") with effective grant dates of August 25, 2025, September 2, 2025 and September 8, 202
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
MNMD(NASDAQ:MNMD) NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that JAMA has published full results from the Company’s positive Phase 2b study of MM120 (lysergide D-tartrate, LSD) in 198 adults with moderate-to-severe GAD. This is the first randomized, placebo-controlled trial to evaluate a single treatment across four dose l
MindMed to Participate in September Investor Conferences
MNMDNEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 Format: Fireside Chat Date and Time: Friday, September 5, 2025 at 10:55 AM ET Location: New York, NY Webcast Link: Cantor
MindMed Announces New Employee Inducement Grants
MNMDNEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of (i) options to purchase an aggregate of 425,450 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the “PSUs”) (assuming achievement at ta
MindMed Announces New Employee Inducement Grants
MNMDNEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the Options), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the appli
Mind Medicine Announced The Appointment Of Brandi L. Roberts As Its Chief Financial Officer (CFO), Effective June 2, 2025
MNMDChardan Capital Maintains Buy on Mind Medicine, Maintains $20 Price Target
MNMDMind Medicine Q1 EPS $(0.35) Beats $(0.38) Estimate
MNMDMindMed Doses First Patient Dosed In Phase 3 Emerge Study Of MM120 For Major Depressive Disorder
MNMDBaird Maintains Outperform on Mind Medicine, Lowers Price Target to $16
MNMDHC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $55 Price Target
MNMDMind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orall
MNMDChardan Capital Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $20
MNMDMindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024
MNMDMind Medicine Receives Letter From Nasdaq Advising Co That It Has Regained Compliance With Nasdaq's Minimum Bid Price Listing Requirement
MNMDUsing LSD To Treat Anxiety Is Showing Some Encouraging Findings In A Clinical Trial
MNMDA new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing
MindMed Announces Results From Collaborators' Placebo-Controlled Investigator-Initiated Trial Published In Peer-Reviewed Journal
MNMDRoth Capital Initiates Coverage On Mind Medicine with Buy Rating, Announces Price Target of $7
MNMD